- Issuer ticker
-
CMPX
- Reported as of
-
08 Feb 2023
- Net transaction value
-
$0
Source evidence
Original filing metadata and source links for verification.
3 source fields
- SEC form
-
4
- Accepted by SEC
-
10 Feb 2023, 15:01:30 UTC
Reporting owner
1 detail
- Reporting owner signature
-
/s/ Neil Lerner, attorney-in-fact
Key filing fact
David M. Wurzer filed Form 4 for Compass Therapeutics, Inc. (CMPX) on 10 Feb 2023.
Key facts
- This page summarizes David M. Wurzer's Form 4 filing for Compass Therapeutics, Inc. (CMPX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 10 Feb 2023, 15:01.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CMPX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +50,000
- Change %
- Price
-
$0.000000
- Shares after
- 50,000
- Date
- 08 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $3.93
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Explanation of responses
1 footnote
SEC remarks
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.